QTc prolongation in patients with COVID-19: a retrospective chart review
- Author:
Suphannika Prateepjarassaeng PORNWATTANAKAVEE
1
;
Watcharapong PRIKSRI
;
Nattawut LEELAKANOK
Author Information
- Publication Type:Original Article
- From:Translational and Clinical Pharmacology 2021;29(4):197-205
- CountryRepublic of Korea
- Language:English
- Abstract: Drug-induced corrected QT (QTc) prolongation can cause Torsade de Pointes (TdP) which leads to severe arrhythmia or sudden cardiac death. However, information on the prevalence of QTc prolongation in coronavirus disease 2019 (COVID-19) patients and risk factors is limited. A retrospective chart review was conducted in COVID-19 patients admitted to Chonburi Hospital from April to October 2020. The outcomes were the incidence of QTc prolongation and prevalence of risk factor QTc prolongation. We included 29 COVID-19 patients. After treatments were initiated, QTc prolongation occurred in 17 patients (58.62%). QT prolongation could be found as early as two days after the treatment initiation (median = 6 days interquartile range [IQR], 4–7). The median QTc interval in those 17 patients increased from 410 (IQR, 399.5–425.0) ms to 460 (453.50–466.50) ms, with the maximum QTc interval of 488 ms. They were treated with multiple drugs that were reported as a cause of QTc prolongation. 64.71% (n = 11) of them were treated with chloroquine. The median TdP risk score in patients with and without QTc prolongation was 3 (IQR, 2–3) and 2 (IQR, 1–2), respectively. The percentage of patients with comorbidities including atrial fibrillation, bradycardia, concomitant use of diuretics, diabetes, electrolyte imbalance was higher in patients with QTc prolongation. COVID-19 patients were treated with multiple drugs that were reported as a cause of QTc prolongation. COVID-19 patients with QTc prolongation had more comorbidities that are risk factors for QTc prolongation.
